AHNAK2 was recently reported as a biomarker for the diagnosis and prognosis of pancreatic ductal adenocarcinoma (PDAC) [11–13], clear cell renal cell carcinoma (ccRCC) [14], thymic carcinoma [15], bladder cancer [16], gastric cancer [17], and uveal melanoma (UM) [18]. Here, AHNAK2 is linked to urinary bladder carcinoma.